论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Hua P, Liu JY, Tao J, Lin XF, Zou RJ, Zhang DW, Yang SR
Received 5 June 2017
Accepted for publication 1 December 2017
Published 20 February 2018 Volume 2018:14 Pages 313—321
DOI https://doi.org/10.2147/TCRM.S143247
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Objective: Retrospective
studies and a meta-analysis were performed to evaluate the safety and
effectiveness of the perioperative administration of recombinant human brain
natriuretic peptide (rhBNP) during cardiac surgery under extracorporeal
circulation.
Methods: Computerized literature searches were performed in Medline, Embase, The
Cochrane Library, CNKI, CBM, and WANFANG to find randomized controlled trials
(RCTs) related to the perioperative administration of rhBNP during cardiac
surgery starting from the database inception until December 2016. Two
researchers independently performed study screening, information extraction,
and quality evaluation according to the inclusion/exclusion criteria, and a
meta-analysis was performed using RevMan 5.2 software.
Results: A total of 12 studies were analyzed, including 12 RCTs and 727 patients.
The meta-analysis results indicated that the perioperative administration of
rhBNP could reduce the occurrence rate of postoperative complications, length
of intensive care unit (ICU) stay, length of hospital stay, and serum creatinine
(Scr) levels, and increase the 24-hour urine volume; however, it did not affect
the postoperative mortality rate.
Conclusion: The perioperative administration of rhBNP during cardiac surgery was
safe and effective, and could improve the prognosis of the patients.
Keywords: recombinant human brain natriuretic peptide, perioperative
administration, meta-analysis